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Two of the key functions of arteries in the brain are (1) the well-recognized supply of
blood via the vascular lumen and (2) the emerging role for the arterial walls as routes
for the elimination of interstitial fluid (ISF) and soluble metabolites, such as amyloid
beta (Aβ), from the brain and retina. As the brain and retina possess no conventional
lymphatic vessels, fluid drainage toward peripheral lymph nodes is mediated via trans-
port along basement membranes in the walls of capillaries and arteries that form the
intramural peri-arterial drainage (IPAD) system. IPAD tends to fail as arteries age but
the mechanisms underlying the failure are unclear. In some people this is reflected in
the accumulation of Aβ plaques in the brain in Alzheimer’s disease (AD) and deposi-
tion of Aβwithin artery walls as cerebral amyloid angiopathy (CAA). Knowledge of the
dynamics of IPAD and why it fails with age is essential for establishing diagnostic tests
for the early stages of the disease and for devising therapies that promote the clear-
ance of Aβ in the prevention and treatment of AD and CAA. This editorial is intended
to introduce the rationale that has led to the establishment of the Clearance of Inter-
stitial Fluid (ISF) and CSF (CLIC) group, within the Vascular Professional Interest Area
of the Alzheimer’s Association International Society to Advance Alzheimer’s Research
and Treatment.
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1 FOCUS OF CLIC
Why is there a need for the CLIC Group within ISTAART’s Vascular PIA? For
20years, the focusof treatments to relieve theburdenof amyloid in the
Alzheimer’s disease (AD) brain has been on immunotherapy, but this
has not been a complete success. Although amyloid beta (Aβ) deposits
are removed from the cerebral cortex, there is a significant increase in
cerebral amyloid angiopathy (CAA) after Aβ immunotherapy; this indi-
cates that Aβ removed from the cortex is deposited in artery walls due
to blockage of the intramural peri-arterial drainage (IPAD) system.1,2
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Shifting the focus from the brain tissue to IPAD may allow us to free
a bottleneck and to increase the effectiveness of immunotherapy. A
similar strategy for improving IPADwill help to prevent the initial age-
related accumulation of Aβ in the brain, thus preventing the develop-
ment of AD.
What are the structure and aims of the group? This is an interdisci-
plinary assembly of scientists, clinicians, and drug developerswho have
already contributed significantly to themechanisms of central nervous
system (CNS) fluidbalanceandexchange, pathologyof cerebrovascular
disease, pathogenesis of Aβ accumulation in AD and cerebral amyloid
angiopathy (CAA), development of AD therapeutics, and delivery of
therapeutics to the brain via intrathecal dosing into the cerebrospinal
fluid (CSF). The role of each member of CLIC will become apparent in
the brief account below of the anatomy, physiology, and pathology of
IPAD and CSF related to AD.
2 MISSION OF THE CLIC GROUP
In the short term, members of the group will establish contacts
and familiarize themselves with the spectrum of research in
IPAD and related fields. Virtual meetings hosting seminars for
greater mutual understanding of respective research focuses are
envisioned.
In the longer term, members of CLIC will form multidisciplinary
groups to gain a greater understanding of the dynamics of IPAD and
CSF circulation in AD and CAA. Each group will establish funding
streams to facilitate collaborativemultidisciplinary research.
The overarching objectives of the CLIC are to:
1. Understand the changes with age in the peripheral physiology that
underly impaired IPAD.
2. Understand the cellular and molecular mechanisms underlying
IPAD physiology in the brain.
3. Establish novel diagnostic tests for AD, CAA, and vasomotion based
on our knowledge of IPAD and the fluid dynamics of CSF.
4. Establish novel therapies that facilitate IPAD for the elimination of
Aβ from the aging brain to prevent or reduce established AD (and
CAA?) pathology.
3 BACKGROUND TO IPAD AND ITS FAILURE
WITH AGE, AD, AND CAA
Aβ and other soluble peptides such as cystatin C are present in the
interstitial fluid (ISF) of the brain. Aβ is normally cleared from the brain
by several mechanisms: it is eliminated across the vascular endothe-
lium via a lipoprotein receptor LRP-1,3 or taken up by microglia, astro-
cytes, and perivascular macrophages.4-6 Another major pathway for
the elimination of Aβ is via ISF drainage. As there are no conventional
lymphatic vessels in the brain, ISF is eliminated along the walls of
cerebral blood vessels. Several anatomical routes have been proposed
for elimination of ISF, including alongside venules (glymphatic system)
and along basement membranes in the walls of capillaries and arter-
ies (IPAD pathways;7,8 Figure 1A,B). Although the exact roles of the
observed drainage pathways have not been fully elucidated, the IPAD
pathway corresponds more closely to neuropathological observations
of vascular Aβ deposits in CAA, which are mainly found in the walls of
capillaries and arteries. IPAD becomes less effective with age, in the
presenceof the apolipoproteinE (APOE)4genotype, andwith apparent
transient overloading after immunotherapy for Aβ7 and CAA-related
inflammation (CAA-ri),8,9 all leading to increased CAA.10-14 IPAD is
not a passive process and the motive force for IPAD is derived from
vascular pulsations. Recently it has been suggested that the sponta-
neous low-frequency contraction and relaxation of vascular smooth
muscle cells (ie, vasomotion), and possibly pericytes, may be impor-
tant drivers for IPAD.15-17 The diversity of the vascular mural cells and
their relative vulnerability during aging is likely to impact the efficiency
of IPAD from different regions of the brain.18,19 Components of the
extracellular matrix within the IPAD pathways, in particular perlecan,
appear to impede the clearance of Aβ.20 Finally, the complex interac-
tions betweenAPOEandAβ, althoughnot fully understood, likely influ-
ence clearance of ISF and Aβ as well.21,22
4 AMYLOID ANGIOPATHY IN RETINAL
ARTERIES
Deposits of Aβ have recently been identified in the tunicamedia of reti-
nal arteries in post-mortem retinae of patients with AD.23,24 Accumu-
lation of Aβ in the retina has been closely linked to an early loss of
retinal vascular smooth muscle cells (vSMC) and pericytes expressing
platelet-derived growth factor receptor (PDGFR)β.25 Furthermore, the
extent of loss of vascular PDGFRβ predicted retinal amyloid angiopa-
thy scores.25 Levels of amyloid angiopathy in the retinal vessels may
prove to be a readily accessible and potentially valuable index of sever-
ity of CAA in the brain.
5 MODELS OF CAA OR SMALL VESSEL DISEASE
While CAA due to accumulation of Aβ in the IPAD pathway is a com-
mon feature of cerebral small vessel disease, CAA is also seen in rarer
disorders involving IPADsuchasFamilial Britishdementia due tomuta-
tions in the BRI gene and Icelandic CAA due to mutations in the gene
encoding the cystatin protein.26,27 It is important to identify appropri-
ate models to study therapeutic targets for CAA or other small vessel
diseases.Different transgenicmousemodels such asAPP/PS1, TgSwDI,
or Tg2576 are used to test individual hypotheses related toCAA, albeit
with limitations.28 Rodent models for the study of vascular dysfunc-
tion include hyperhomocysteinemia and hypoperfusion due to occlu-
sion of a carotid artery.29-32 In addition, non-human primate models
are known to develop extensive CAA thus offering potential preclini-
cal avenues for investigation, especially in the context of white matter
lesions.33,34 Intramural accumulation of cystatin amyloid aggregates in
Icelandic CAA are also observed in skin vessels, suggesting that in vitro
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F IGURE 1 A, Intramural peri-arterial drainage (IPAD) pathways for the lymphatic drainage of interstitial fluid (ISF) and soluble amyloid beta
(Aβ) from the brain. Right side of diagram: ISF and Aβ (green line and arrows) pass from the extracellular spaces of the brain to drain along the walls
of capillaries and arteries ultimately to the cervical lymph nodes adjacent to arteries under the base of the skull. Details of the IPAD pathway are
shown in (B). Left side shows how cerebrospinal fluid (CSF) enters the brain along the outer aspects of penetrating arteries and passes into the ISF
of the brain parenchyma (details in [C]) and then flows out of the brain along IPAD pathways (green line and arrows). B) Details of the IPAD
pathway, cerebral amyloid angiopathy (CAA) and LRP-1-related absorption for Aβ. Soluble Aβ (light blue arrow), produced by cells in the brain, is
absorbed into the blood involving LRP-1 as one of the pathways for elimination of Aβ. Another major pathway is by IPAD (green line and arrows).
Aβ in the ISF enters the basementmembranes of endothelial cells in the walls of capillaries. Contractile pericytes surround capillaries andmay
supply themotive force for IPAD in capillaries. Aβ then rapidly passes into basementmembranes (100 to 150 nm thick) surrounding smooth
muscle cells (SMC)s in the tunicamedia of cerebral arteries. Changes occur in the walls of arteries as they age and IPAD is impaired resulting in the
deposition of fibrillar Aβ in the IPAD pathways as CAA (green asterisks). As more Aβ is deposited and the severity of CAA increases, the wall of the
artery is disrupted, SMCs are replaced by Aβ and IPAD is further impaired. The yellow line passing along the IPAD pathway shows howCSF that
has entered the ISF of the brain also drains from the brain along IPAD pathways in artery walls. SMCs in the tunica media of arteries supply the
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models of this disorder could provide convenient platforms to study
mechanistic properties of affected vessels.35
6 DEVELOPING NOVEL THERAPEUTIC
STRATEGIES
New therapeutic avenues for CAA (and AD) that act via IPAD
include interventions modulating vasomotion, the postulated motive
force of IPAD. This could potentially be accomplished by enhanc-
ing low-frequency oscillations of the vascular smooth muscle cells
through neurovascular coupling or during sleep,36 or by noradrener-
gic innervation of cortical vSMCs.37 Other potential therapeutic tar-
gets are intracellular mitochondrial systems,38 chaperone molecules
such as clusterin,39,40 or combination therapies.41 Pharmaceuti-
cal approaches may include vasoactive drugs that promote IPAD,
resulting in maintenance of vascular integrity and reduction of Aβ
deposits.42
Other proposed mechanisms for vascular dysfunction in the brain
include mitochondrial dysfunction, metabolic failure, autoimmunity,
initiation of mechanisms of cell death and inflammation (with involve-
ment of the neurovascular unit, including endothelial cells, vSMCs, per-
icytes, as well as glial cells). Each of these processes may contribute to
impaired clearance of fluids, including soluble Aβ and hyperphosphory-
lated tau from the brain.43,44 Multiple studies are currently evaluating
strategies to ameliorate these pathways.
7 CEREBROSPINAL FLUID
CSF is produced by the choroid plexus and while some CSF may pass
into venous blood via arachnoid villi and granulations in humans, CSF
also drains along lymphatics located in the dural meninges and in cra-
nial and spinal nerve sheaths en route to regional head, neck, and
perispinal lymph nodes.45-47 The route along channels that are adja-
cent to olfactory nerves entering the nasal mucosa is emerging as an
important pathway for the diagnosis of AD.48
The relative contribution of these drainage pathways to overall
clearance of CSF and solutes as well as a specific point of anatomi-
cal confluence between vascular wall and lymphatic routes remains to
be further elucidated. Measures of overall clearance of molecules via
the CSF to the periphery or along each of these specific routes could
emerge as important biomarkers for diagnosing failure of clearance of
fluid from the CNS in diseases such as AD.48-51
8 INTERCONNECTIONS BETWEEN CSF AND ISF
IN THE BRAIN
In vivo imaging data from human studies show that molecules within
the CSF are in direct communication with the ISF.52,53 In vivo imag-
ing studies showed that tracers administered into CSF enter the
brain along the periarterial pial-glial basement membranes between
pia mater coating the arteries and the glia limitans of the cerebral
cortex.54,55 These boundaries give rise to a periarterial compartment
filled with extracellular matrix around arteries (observed as “perivas-
cular spaces” on in vivo imaging56), facilitating the transport of CSF
into the brain.8 After tracers have entered the parenchyma from the
CSF they mix with ISF,55 prior to leaving the brain by IPAD55 (Fig-
ure 1a-c). As suggested by the glymphatic system, an alternative clear-
ance route for ISFmaybe alongside thewalls of venules. Further exper-
imental studies are needed to fully elucidate the relative contribution
of venules and arteries to the clearance of ISF from the parenchyma.
There is an increased incidence of AD pathology, including CAA, in
patients with idiopathic normal pressure hydrocephalus (iNPH), most
likely as a result of disturbances in the dynamics of CSF-ISF.57 Patients
with iNPH could therefore be a valuablemodel for the study of interac-
tions CSF–ISF.
As CSF enters the brain along basement membranes surrounding
the walls of cortical arteries, this represents an important pathway
for drug delivery, including novel antisense oligonucleotides.49 Drugs
injected into the CSF may also have unique access to influence the
dynamics of ISF clearance along IPAD pathways.
There are meningeal lymphatics in the dural lining of the skull, but
their role in clearing ISF is unclear.58 Tracers injected into the CSF
drain into parasaggital lymphatics in the dura and reach cervical lymph
nodes.53
9 CAA-RI AND ARIA: CLINICAL–RADIOLOGICAL
ABNORMALITIES POTENTIALLY RELATED TO THE
FAILURE OF DRAINAGE OF FLUID FROM THE
BRAIN
It is widely accepted that amyloid-related imaging abnormalities
(ARIA) represent a major unwanted effect of Aβ immunotherapy for
AD. The features of both ARIA-E, in which there is evidence of vaso-
genic edema and inflammation, and ARIA-H, in which there is evi-
dence of hemosiderin deposits, microhemorrhages, and cortical super-
ficial siderosis suggest the disruption of the normal interactions among
motive force for IPAD and have both adrenergic and cholinergic innervations. C, Entry of CSF into the brain along periarterial pial–glial basement
membranes. As arteries enter the surface of the cerebral cortex they are coated by a layer of pia mater that is firmly associated with the basement
membranes of the glia limitans on the surface of the brain. There are no perivascular spaces around cortical arterioles so tracers injected into the
CSF enter the brain along the periarterial pial–glial basementmembranes andmix with the ISF in the brain parenchyma. CSF tracers are then
eliminated from the brain along IPAD pathways. This route could be used to deliver drugs to increase the efficiency of elimination of Aβ along aging
IPAD pathways. PVM, perivascular macophage; SAS, subarachnoid space
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ISF, CSF, and walls of blood vessels.7,59 Both ARIA-E and ARIA-
H phenomena have been demonstrated spontaneously in CAA-ri, a
rare autoimmune encephalopathymediated by autoantibody targeting
cerebrovascular Aβ.8
Like immunotherapy-induced ARIA, it is hypothesized that
increased anti-Aβ auto antibodies in the CSF promote the clear-
ance of Aβ plaques from the CNS as evidenced by the increased
amount of soluble Aβ40 and Aβ42 and reduced Aβ-PET uptake.
According to the “ARIA Paradox” pathogenic model9 the initiating
factors and immune-mediated mechanisms of CAA-ri and ARIA are
thought to be a complicated mixture of genetic, vascular, and immuno-
logical risk factors closely related to the Aβ burden and the dose- and
time-related effects of anti-Aβ antibodies.59 It is thus likely that the
severity of CAA and the CAA-related impairment of neurovascular
coupling functions, including the complex interplay among microglia,
astrocytes, endothelial, and vSMC are the game-changers in deter-
mining vascular dysfunction and impairment of clearance of Aβ and
hyperphosphorylated tau from the brain.60,61
To this end, anti-Aβ autoantibodies and CAA-ri could offer a unique
possibility to explore the relationships between pathways of Aβ clear-
ance and enable development of innovative therapies, representing a
human spontaneousmodel of Aβ immunotherapy.
10 CONCLUSION
Our interdisciplinary group aims to further the understanding of how
ISF and CSF are involved in the pathology of AD and related demen-
tias and how ISF andCSFmay be harnessed for diagnostic tests and for
disease-modifying therapies.
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